• uconn health
Page content relevant to:

IBC Meeting Dates/Meeting Minutes

The UConn Health Institutional Biosafety Committee (IBC) is federally mandated to review work with recombinant or synthetic nucleic acids.

This committee meets monthly, usually on the second Thursday of the month. Exceptions are noted (*). Receive forms from and submit to ibc@uchc.edu by the submission deadline.

Upcoming meetings 2026/7:

Date Time Location Submission Deadline
January 8, 2026 3:10 pm WebEx December 30, 2025
February 12, 2026 3:10 pm WebEx February 3, 2026
March 12, 2026 3:10 pm WebEx March 3, 2026
April 9, 2026 3:10 pm WebEx May 31, 2026
May 14, 2026 3:10 pm WebEx May 5, 2026
June 11, 2026 3:10 pm WebEx June 2, 2026
July 9, 2026 3:10 pm WebEx June 30, 2026
August 13, 2026 3:10 pm WebEx August 3, 2026
September 10, 2026 3:10 pm WebEx September 1, 2026
October 8, 2026 3:10 pm WebEx September 29, 2026
November 12, 2026 3:10 pm WebEx November 3, 2026
December 10, 2026 3:10 pm WebEx December 1, 2026
January 14, 2027 3:10 pm WebEx January 5, 2027

 

If you are a person interested in or concerned about this type of research, you are invited to attend a meeting of the UCONN Health IBC. Meetings will be held virtually for the foreseeable future. Please contact IBC@uchc.edu for more information.

WCG Institutional Biosafety Committee Services periodically convenes open meetings regarding a human gene transfer study at UCONN Health. Announcements about these meetings will appear below when they are scheduled.

Meeting Minutes:

2025 2026 2027
January 2026
February 2026
March 2026
April 2026
May 2026
June 2025 June 2026
July 2025 July 2026
August 2025 August 2026
September 2025 September 2026
October 2025 October 2026
November 2025 November 2026
December 2025 December 2026

As required by NOT-OD-25-082, effective June 1, 2025, approved IBC meeting minutes may be accessed by the public.

FAQs about IBC meetings and minutes is available on the NIH OSP website. In particular, refer to “What is the expected content of IBC minutes?” UCH follows this guidance.